Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A diffuse large B-cell lymphoma that is localized to the lungs at the time of presentation. Signs and symptoms include cough, dyspnea, and hemoptysis.
Biomarker and diagnostic research for primary pulmonary diffuse large B-cell lymphoma has been reported in the published literature.
No clinical trials have been registered for primary pulmonary diffuse large B-cell lymphoma.
132 publications have been identified in PubMed for primary pulmonary diffuse large B-cell lymphoma. Research spans Case Report / Case Series (42%), Epidemiology / Natural History (17%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 56 | 42% |
Data assembled from 2 of 12 sources · Last updated Sep 18, 2026, 7:13 PM UTC
Disease patterns and progression |
23 |
17% |
Laboratory research | 22 | 17% |
Testing and diagnosis research | 12 | 9% |
Clinical study results | 12 | 9% |
Research summaries | 5 | 4% |
New treatment approaches | 2 | 2% |
Li J (2026). [PMID: 41979125](https://pubmed.ncbi.nlm.nih.gov/41979125/). *Biomol Biomed*. [Diagnostic / Biomarker]
Sekiguchi Y (2026). [PMID: 41555173](https://pubmed.ncbi.nlm.nih.gov/41555173/). *Gan To Kagaku Ryoho*. [Case Report / Case Series]
Fahmy V (2026). [PMID: 41939553](https://pubmed.ncbi.nlm.nih.gov/41939553/). *Cureus*. [Case Report / Case Series]
Qin F (2026). [PMID: 41967136](https://pubmed.ncbi.nlm.nih.gov/41967136/). *J Natl Cancer Inst*. [Basic Science / Preclinical]
Xanthopoulou G (2026). [PMID: 42147594](https://pubmed.ncbi.nlm.nih.gov/42147594/). *Cureus*. [Case Report / Case Series]
Fujii T (2026). [PMID: 41850831](https://pubmed.ncbi.nlm.nih.gov/41850831/). *Intern Med*. [Case Report / Case Series]
Wang L (2026). [PMID: 41836964](https://pubmed.ncbi.nlm.nih.gov/41836964/). *Frontiers in medicine*. [Case Report / Case Series]
Chen J (2026). [PMID: 41767535](https://pubmed.ncbi.nlm.nih.gov/41767535/). *Front Med (Lausanne)*. [Case Report / Case Series]
Ibrahim EA (2026). [PMID: 41712976](https://pubmed.ncbi.nlm.nih.gov/41712976/). *J Med Imaging Radiat Sci*. [Review / Meta-Analysis]
Tariq MA (2026). [PMID: 42109955](https://pubmed.ncbi.nlm.nih.gov/42109955/). *Cureus*. [Case Report / Case Series]
AI-curated news mentioning primary pulmonary diffuse large B-cell lymphoma
Updated Sep 16, 2026
A recent study analyzes prognostic factors and survival rates in HHV8 positive diffuse large B cell lymphoma using national cancer database data. The findings may inform treatment strategies and patient management for this rare lymphoma subtype.
A recent study highlights hemophagocytic lymphohistiocytosis as a potential initial presentation of occult diffuse large B-cell lymphoma, posing significant diagnostic challenges. This finding underscores the need for heightened awareness among clinicians to improve early detection and treatment outcomes.
A recent study highlights a rare presentation of diffuse large B-cell lymphoma, where peritoneal lymphomatosis can mimic complicated hydatid cysts on imaging. This finding emphasizes the need for careful differential diagnosis in similar cases.
ADC Therapeutics faces significant setbacks as its lymphoma drug Zynlonta, when combined with rituximab, resulted in 27 patient deaths and showed no overall survival benefit in diffuse large B cell lymphoma. This raises concerns about its viability as a second-line treatment.